Covalent inhibitors: a rational approach to drug discovery
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
In this review we provide a brief historic overview of covalent inhibitors and summarize recent advances focusing on developments in the last decade. Applications in challenging targets and future perspectives are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past 30 years, the rational design of covalent drugs has garnered increased interest, and covalently targeting non-conserved amino acids to increase selectivity has become commonplace2,5.”
From Advances in covalent drug discovery (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Covalent drugs also exhibit impressive performance in selective targeting,521 potentially providing novel inhibitory approaches for kinases such as CK1, which have previously only been targeted with non-covalent ATP competitive inhibitors.522”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
The cited source says what the claim attributes to it.
In the citing paper
“Covalent inhibitors, which form covalent bonds with their target proteins, rely on the specificity and stability of these interactions to exhibit superior potency, selectivity, and duration of action. This mechanism offers patients a convenient therapeutic option.521,565”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
PENICILLIN-BINDING PROTEINS AND THE MECHANISM OF ACTION OF BETA-LACTAM ANTIBIOTICS
Waxman, D. J., & Strominger, J. L. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.004141 · Cited by 721
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · cited 1×
“In 2013, Walter et al.13 showed that a novel covalent inhibitor, CO-1686, inhibits a drug-resistance mutant of T790M EGFR.”
Background
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Bicyclobutanes: from curiosities to versatile reagents and covalent warheads
Kelly, C. B., Milligan, J. A., Tilley, L. J., & Sodano, T. M. (2022) · Chemical Science · doi:10.1039/d2sc03948f · Cited by 334
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
The importance of sulfur-containing motifs in drug design and discovery
Mustafa, M., & Winum, J.-Y. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2044783 · Cited by 249
Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
Sharma, P., LaRosa, C., Antwi, J., Govindarajan, R., & Werbovetz, K. A. (2021) · Molecules · doi:10.3390/molecules26144213 · Cited by 207
Covalent targeted radioligands potentiate radionuclide therapy
Cui, X.-Y., Li, Z., Kong, Z., Liu, Y., Meng, H., Wen, Z., Wang, C., Chen, J., Xu, M., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07461-6 · Cited by 195
Liu, Y., Guo, Q., Yang, H., Zhang, X.-W., Feng, N., Wang, J.-K., Liu, T., Zeng, K., & Tu, P. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00107 · Cited by 167
Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01070 · Cited by 169
Robello, M., Barresi, E., Baglini, E., Salerno, S., Taliani, S., & Settimo, F. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01808 · Cited by 143
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Mori, Y., Novruzov, E., Schmitt, D. R., Cardinale, J., Watabe, T., Choyke, P. L., Alavi, A. A., Haberkorn, U., & Giesel, F. L. (2024) · npj Imaging · doi:10.1038/s44303-024-00053-z · Cited by 140
“Covalent targeted radioligand (CTR) is a novel strategy for the prolonged binding of radioligands to their targets 223,224 .”
Nitriles: an attractive approach to the development of covalent inhibitors
Bonatto, V., Lameiro, R. F., Rocho, F. D. R., Lameira, J., Leitão, A., & Montanari, C. A. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00204c · Cited by 137
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 108
“Theoretically, irreversible inhibitors exhibit stronger affinity and higher selectivity than reversible inhibitors because irreversible inhibitors can form covalent bonds with specific amino acids in a time‐dependent manner.(49) Gray's group investigated the binding mode of KRAS covalent inhibitor 10 and observed that…”
BackgroundRecent advances in the development of covalent inhibitors
Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00068c · Cited by 116
Genetic Code Expansion: Recent Developments and Emerging Applications
Huang, Y., Zhang, P., Wang, H., Chen, Y., Liu, T., & Luo, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00216 · Cited by 114
Gilbert, K. E., Vuorinen, A., Aatkar, A., Pogány, P., Pettinger, J., Grant, E. K., Kirkpatrick, J. M., Rittinger, K., House, D., Burley, G. A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00633 · Cited by 115
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
Picarazzi, F., Vicenti, I., Saladini, F., Zazzi, M., & Mori, M. (2020) · Molecules · doi:10.3390/molecules25235695 · Cited by 100
“In the development of TCIs, the target’s features should be thoroughly examined because not all the target proteins are suitable for this type of inhibition mechanism due to the high turn-over or degradation rate [92].”
BackgroundZaidman, D., Gehrtz, P., Filep, M., Fearon, D., Gabizon, R., Douangamath, A., Prilusky, J., Duberstein, S., Cohen, G., Owen, C. D., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.018 · Cited by 88
“, 2019), (4) targeting shallow binding sites (Sutanto et al., 2020), and (5) covalent binding can enable targeting of especially challenging targets such as the G12C oncogenic”
BackgroundXiong, Y., Zhu, G., Zhang, Y.-N., Hu, Q., Wang, H., Yu, H.-N., Qin, X., Guan, X., Xiang, Y., Tang, H. R., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.167 · Cited by 76
“The covalent inhibitors possessed several inherent advantages (such as high specificity, good inhibition potency, and durable interactions) [14], which could bring benefits to both anti-COVID-”
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Xie, Z., Hou, S., Yang, X., Duan, Y., Han, J., Wang, Q., & Liao, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02190 · Cited by 80
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Yaashikaa, P. R., Devi, M. K., & Kumar, P. S. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134390 · Cited by 79
Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase
Kwai, B. X. C., Collins, A. J., Middleditch, M., Sperry, J., Bashiri, G., & Leung, I. K. H. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00301h · Cited by 75
Chemical technology principles for selective bioconjugation of proteins and antibodies
Chauhan, P. S., Ragendu, V., Kumar, M., Molla, R., Mishra, S. D., Basa, S., & Rai, V. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00715d · Cited by 81
Applications of covalent chemistry in targeted protein degradation
Lu, D., Yu, X., Lin, H., Cheng, R., Monroy, E. Y., Qi, X., Wang, M. C., & Wang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00362g · Cited by 72
Dehydrogenative Pd and Ni Catalysis for Total Synthesis
Huang, D. S., & Newhouse, T. R. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00787 · Cited by 59
Covalent drugs targeting histidine – an unexploited opportunity?
Che, J., & Jones, L. H. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00258b · Cited by 61
CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
Gao, M., Moumbock, A. F. A., Qaseem, A., Xu, Q., & Günther, S. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab868 · Cited by 56
Tunable Cysteine-Targeting Electrophilic Heteroaromatic Warheads Induce Ferroptosis
Karaj, E., Sindi, S. H., Kuganesan, N., Perera, L., Taylor, W. R., & Tillekeratne, L. M. V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00909 · Cited by 57
Chen, C., Yin, Y., Shi, G., Zhou, Y. J., Shao, S., Wei, Y., Wu, L., Zhang, D., Sun, L., & Zhang, T. (2022) · Science Advances · doi:10.1126/sciadv.abo4363 · Cited by 53
“Acrylamide, with potently electrophilic properties, is often used as covalent warhead to design selective JAK3 kinase inhibitors ( 37 ).”
Profiling the proteome-wide selectivity of diverse electrophiles
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01902-z · Cited by 117
“Covalent inhibitors that do not rely on hijacking enzyme activity have so far almost exclusively targeted cysteine residues 7 .”
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
Thiyagarajan, T., Ponnusamy, S., Hwang, D., He, Y., Asemota, S., Young, K. L., Johnson, D. L., Bocharova, V., Zhou, W., Jain, A. K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211832120 · Cited by 52
Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo
de Boer, C., Armstrong, Z., Lit, V. A. J., Barash, U., Ruijgrok, G., Boyango, I., Weitzenberg, M. M., Schröder, S. P., Sarris, A. J. C., Meeuwenoord, N. J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203167119 · Cited by 51
“by cells requires a broad complement of proteases and glycosidases, thereby mimicking some aspects of metastasis in vivo (51).”
BackgroundHeatwave Variability and Structure in South Africa during Summer Drought
Mbokodo, I. L., Bopape, M.-J. M., Ndarana, T., Mbatha, S. M. S., Muofhe, T. P., Singo, M. V., Xulu, N. G., Mohomi, T., Ayisi, K. K., & Chikoore, H. (2023) · Climate · doi:10.3390/cli11020038 · Cited by 48
“The co-occurrence of HWs and droughts is also known to contribute to the occurrence of wildfires [47,48], which in turn affect agricultural yields and rangelands for livestock.”
Yu, W., Zhao, Y., Ye, H., Wu, N., Liao, Y., Chen, N., Li, Z., Wan, N., Hao, H., Yan, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00954 · Cited by 46
Recent Advances on Targeting Proteases for Antiviral Development
Borges, P. H. O., Ferreira, S. B., & Silva, F. P. (2024) · Viruses · doi:10.3390/v16030366 · Cited by 51
“However, in some cases, prolongation of the therapeutic response is desired, which can be achieved by increasing the time available for this small molecule to interact with the protein’s active site [59].”
BackgroundCHARMM-GUI PDB Reader and Manipulator: Covalent Ligand Modeling and Simulation
Kong, L., Park, S., & Im, W. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168554 · Cited by 48
The role of quantum chemistry in covalent inhibitor design
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2021) · International Journal of Quantum Chemistry · doi:10.1002/qua.26768 · Cited by 48
Profiling the proteome-wide selectivity of diverse electrophilesPreprint
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-w7rss-v2 · Cited by 55
Covalent Inhibitors: To Infinity and Beyond
Raouf, Y. S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01308 · Cited by 50
Identification of Covalent Cyclic Peptide Inhibitors in mRNA Display
Iskandar, S. E., Chiou, L. F., Leisner, T. M., Shell, D. J., Norris-Drouin, J. L., Vaziri, C., Pearce, K. H., & Bowers, A. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04833 · Cited by 45
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
Ge, R., Shen, Z., Yin, J., Chen, W., Zhang, Q., An, Y., Tang, D., Satz, A. L., Su, W., & Kuai, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.01.001 · Cited by 43
Baldwin, E. T., Götte, M., Tchesnokov, E. P., Arnold, E., Hagel, M., Nichols, C. E., Dossang, P., Lamers, M. B. A. C., Wan, P., Steinbacher, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200260119 · Cited by 47
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 47
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications
Baldi, S., Long, N., Ma, S., Liu, L., Al-Danakh, A., Qin, Y., Deng, X., Xie, J., & Tang, H. (2025) · Research · doi:10.34133/research.0747 · Cited by 59
“Ibrutinib forms a covalent bond with Cys 481 through an acrylamide war-head, thereby inhibiting B cell receptor activation in lymphomas [ 172 ].”
Li, S., Zhang, P., Xu, F., Hu, S., Liu, J.-C., Tan, Y., Tu, Z., Sun, H., Zhang, Z., He, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00272 · Cited by 40
USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK
Liu, J., Hu, X., Luo, K., Xiong, Y., Chen, L., Wang, Z., Inuzuka, H., Qian, C., Yu, X., Xie, L., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02373 · Cited by 54
Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach
Ma, Z., Zhou, M., Chen, H., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02975 · Cited by 45
London, N. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00570 · Cited by 39
Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs
Wang, N., & Wang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102106 · Cited by 36
Profiling the Proteome-Wide Selectivity of Diverse Electrophiles
Zanon, P. R. A., Yu, F., Musacchio, P., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · doi:10.26434/chemrxiv.14186561.v1 · Cited by 35
Late‐Stage C−H Activation of Drug (Derivative) Molecules with Pd(ll) Catalysis
Shim, S. Y. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202302620 · Cited by 39
Hoyt, K. W., Urul, D. A., Ogboo, B. C., Wittlinger, F., Laufer, S., Schaefer, E., May, E. W., & Heppner, D. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01502 · Cited by 37
CovBinderInPDB: A Structure-Based Covalent Binder Database
Guo, X.-K., & Zhang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01216 · Cited by 37
Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides
Zhang, M. Y., Yang, H., Ortiz, G., Trnka, M. J., Petronikolou, N., Burlingame, A. L., DeGrado, W. F., & Fujimori, D. G. (2022) · Chemical Science · doi:10.1039/d2sc00555g · Cited by 34
Traceless cysteine-linchpin enables precision engineering of lysine in native proteins
Reddy, N. C., Molla, R., Joshi, P. N., Sajeev, T. K., Basu, I., Kawadkar, J., Kalra, N., Mishra, R. K., Chakrabarty, S., Shukla, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33772-1 · Cited by 34
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Yan, W., Zheng, Y., Dou, C. R., Zhang, G., Arnaout, T., & Cheng, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00106-y · Cited by 38
Aboukhatwa, S. M., Sidhom, P. A., Angeli, A., Supuran, C. T., & Tawfik, H. O. (2023) · ACS Omega · doi:10.1021/acsomega.2c07285 · Cited by 34
Friedel–Crafts reactions for biomolecular chemistry
Ohata, J. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00406j · Cited by 35
Emerging drug design strategies in anti-influenza drug discovery
Liu, C., Hu, L., Dong, G., Zhang, Y., da Silva‐Júnior, E. F., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.010 · Cited by 37
Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides
Craven, G. B., Briggs, E. L., Zammit, C. M., McDermott, A., Greed, S., Affron, D. P., Leinfellner, C., Cudmore, H., Tweedy, R., Luisi, R., et al. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00373 · Cited by 36
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Rathod, L. S., Dabhade, P. S., & Mokale, S. N. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103557 · Cited by 33
Protein Electric Fields Enable Faster and Longer-Lasting Covalent Inhibition of β-Lactamases
(2022) · doi:10.1021/jacs.2c09876 · Cited by 31
Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions
Deng, H., Han, Y., Liu, L., Zhang, H., Liu, D., Wen, J., Huang, M., & Zhao, L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01998 · Cited by 34
Sherborne, G. J., Kemmitt, P. D., Prentice, C., Zysman‐Colman, E., Smith, A. D., & Fallan, C. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202207829 · Cited by 31
Deni, I., Stokes, B. H., Ward, K. E., Fairhurst, K. J., Pasaje, C. F. A., Yeo, T., Akbar, S., Park, H., Muir, R. K., Bick, D. S., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.03.002 · Cited by 31
“We note that covalent irreversible inhibitors that are selective for parasite proteasomes have the caveat that any off-target binding to host proteasomes or other host proteases can carry an increased risk of toxicity compared with other types of inhibitors, requiring additional scrutiny during any further drug develo…”
Bonatto, V., Shamim, A., Rocho, F. D. R., Leitão, A., Luque, F. J., Lameira, J., & Montanari, C. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00515 · Cited by 32
Karaj, E., Sindi, S. H., & Tillekeratne, L. M. V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116721 · Cited by 30
Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors
Zhong, H. A., & Almahmoud, S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076023 · Cited by 29
“reported at least 50 covalent drugs that have been approved by the US Food and Drug Administration (FDA) [43].”
BackgroundInfluentialVerma, V. S., Pandey, A., Jha, A. K., Badwaik, H. R., Alexander, A., & Ajazuddin, M. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04895-6 · Cited by 34
Lloyd, M. D., Yevglevskis, M., Nathubhai, A., James, T. D., Threadgill, M. D., & Woodman, T. J. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00540a · Cited by 29
CYP1A inhibitors: Recent progress, current challenges, and future perspectives
Dai, Z., Wu, Y., Xiong, Y., Wu, J., Wang, M., Sun, X., Ding, X., Yang, L., Sun, X., & Ge, G. (2023) · Medicinal Research Reviews · doi:10.1002/med.21982 · Cited by 27
Chemical technologies for precise protein bioconjugation interfacing biology and medicine
Kumar, M., Reddy, N. C., & Rai, V. (2021) · Chemical Communications · doi:10.1039/d1cc02268g · Cited by 29
Shawky, A. M., Almalki, F. A., Alzahrani, H. A., Abdalla, A. N., Youssif, B. G. M., Ibrahim, N. A., Gamal, M., El-Sherief, H. A. M., Abdel‐Fattah, M. M., Hefny, A. A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116704 · Cited by 27
Zhang, Z., Wang, Y., Chen, X., Song, X., Tu, Z., Chen, Y., Zhang, Z., & Ding, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116457 · Cited by 24
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)
Rocho, F. D. R., Bonatto, V., Lameiro, R. F., Lameira, J., Leitão, A., & Montanari, C. A. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2040480 · Cited by 27
“Despite being avoided by the pharmaceutical companies until the past decade due to concerns of side effects, the scenario has changed a lot since then, with over 50 covalent drugs currently approved by the FDA [49].”
Electrophilic Natural Products as Drug Discovery Tools
Gehrtz, P., & London, N. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.008 · Cited by 25
Profiling the proteome-wide selectivity of diverse electrophilesPreprint
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · doi:10.33774/chemrxiv-2021-w7rss-v2 · Cited by 25
Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs
Liberelle, M., Toulotte, F., Renault, N., Gelin, M., Allemand, F., Melnyk, P., Guichou, J., & Cotelle, P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00075 · Cited by 25
Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors
Lang, P. A., Raj, R., Tumber, A., Lohans, C. T., Rabe, P., Robinson, C. V., Brem, J., & Schofield, C. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117310119 · Cited by 24
“, sulfonamide antibiotics (23)] and there is growing interest in covalently acting drugs (24, 25), sulfones are rare in drugs and, as far as we are aware, sulbactam and tazobactam are the only clinically approved sulfone-containing drugs working by covalent reaction with their targets (26–28).”
BackgroundNever Gonna Give You Up – Current Developments in Covalent Protein Kinase Inhibitors
Hillebrand, L., & Gehringer, M. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.435 · Cited by 25
Discovery of Potent Pyrazoline‐Based Covalent SARS‐CoV‐2 Main Protease Inhibitors**
Moon, P. J., Zammit, C. M., Shao, Q., Dovala, D., Boike, L., Henning, N. J., Knapp, M. S., Spradlin, J. N., Ward, C. C., Wolleb, H., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300116 · Cited by 23
Koperniku, A., Garcia, A. A., & Mochly‐Rosen, D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01577 · Cited by 26
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Cheke, R. S., & Kharkar, P. S. (2023) · Drug Development Research · doi:10.1002/ddr.22132 · Cited by 26
“Approximately 28% of TCIs target oncology ‐ related targets, 23% are focused on the central nervous system (CNS) and related disorders, 21% are antibiotics, and around 11% are employed in treating gastrointestinal disorders (Sutanto et al., 2020).”
BackgroundCryptic enzymatic assembly of peptides armed with β-lactone warheads
Xu, G., Torri, D., Cuesta, S. A., Panda, D., Yates, L. R. L., Zallot, R., Bian, K., Jia, D., Iorgu, A. I., Levy, C., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01657-7 · Cited by 22
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Tao, H., Yang, B., Farhangian, A., Xu, K., Li, T., Zhang, Z., & Li, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02760 · Cited by 22
Improved Electrophile Design for Exquisite Covalent Molecule Selectivity
Montaño, J. L., Wang, B. J., Volk, R. F., Warrington, S. E., Garda, V. G., Hofmann, K. L., Chen, L. C., & Zaro, B. W. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00980 · Cited by 21
HCovDock: an efficient docking method for modeling covalent protein–ligand interactions
Wu, Q., & Huang, S. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac559 · Cited by 23
Thomas, R. P., Grant, E. K., Dickinson, E. R., Zappacosta, F., Edwards, L. J., Hann, M. M., House, D., Tomkinson, N. C. O., & Bush, J. T. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00453d · Cited by 22
Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization
Qian, C., Wang, Z., Xiong, Y., Zhang, D., Zhong, Y., Inuzuka, H., Qi, Y., Xie, L., Chen, X., Wei, W., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c01662 · Cited by 23
Fragment-based screening: A new paradigm for ligand and target discovery
Knight, S., Gianni, D., & Hendricks, A. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2021.10.011 · Cited by 21
Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
Liu, Y., Zhang, M., Jang, H., & Nussinov, R. (2022) · Protein Science · doi:10.1002/pro.4504 · Cited by 20
Zhang, B., Zhu, C., Chan, A. S. C., & Lu, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115457 · Cited by 20
Cores, Á., Abril, S., Michalska, P., Duarte, P., Olives, A. I., Martín, M. A., Villacampa, M., Leon, R. M., & Menéndez, J. C. (2021) · Antioxidants · doi:10.3390/antiox10060941 · Cited by 21
“It is relevant to note that, despite their reputation for toxicity, interest in covalent drugs has undergone a renaissance, and about 30% of the recently marketed drugs belong to this class [24,25].”
BackgroundLabarre, A., Stille, J. K., Patrascu, M. B., Martins, A., Pottel, J., & Moitessier, N. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00701 · Cited by 21
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 23
Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor
Yuhas, S. C., Laverty, D. J., Lee, H., Majumdar, A. K., & Greenberg, M. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02453 · Cited by 19
Metadata
- Authors
- Sutanto, F., Konstantinidou, M., & Dömling, A.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dömling, Alexander
- Venue
- RSC Medicinal Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 8
- Pages
- 876-884
- ISSN
- 2632-8682 (ISSN-L)
- PMC
- PMC7557570
- OpenAlex
- W3038238188
- Cited by
- 389
- References
- 27
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 72 · 2023: 64 · 2022: 75 · 2021: 48 · 2020: 5
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- RSC Medicinal Chemistry (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (2R01GM097082-05)
- KWF Kankerbestrijding (10504)
- Lembaga Pengelola Dana Pendidikan
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent inhibitors, drug discovery, off-target toxicity, cancer drug targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.